 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || ION582 / Ionis, Biogen
Trial completion date, Trial primary completion date: HALOS: A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Multiple Ascending Doses of ION582 in Participants With Angelman Syndrome (clinicaltrials.gov) - Mar 21, 2024
P1/2, N=51, Active, not recruiting, Sponsor: Ionis Pharmaceuticals, Inc.
Trial completion date: Jan 2025 --> Mar 2029 | Trial primary completion date: Jan 2025 --> Mar 2029
- || ION582 / Ionis, Biogen
Enrollment closed: HALOS: A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Multiple Ascending Doses of ION582 in Participants With Angelman Syndrome (clinicaltrials.gov) - Dec 11, 2023
P1/2, N=51, Active, not recruiting, Sponsor: Ionis Pharmaceuticals, Inc.
Trial completion date: Jan 2025 --> Mar 2029 | Trial primary completion date: Jan 2025 --> Mar 2029 Recruiting --> Active, not recruiting
- | ION582 / Ionis, Biogen
Trial completion date, Trial primary completion date: HALOS: A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Multiple Ascending Doses of ION582 in Participants With Angelman Syndrome (clinicaltrials.gov) - Jan 9, 2023
P1/2, N=44, Recruiting, Sponsor: Ionis Pharmaceuticals, Inc.
Recruiting --> Active, not recruiting Trial completion date: Dec 2023 --> Jan 2025 | Trial primary completion date: Jul 2023 --> Jan 2025
- || ION582 / Ionis, Biogen
Enrollment open: HALOS: A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Multiple Ascending Doses of ION582 in Participants With Angelman Syndrome (clinicaltrials.gov) - Dec 29, 2021
P1/2, N=44, Recruiting, Sponsor: Ionis Pharmaceuticals, Inc.
Trial completion date: Dec 2023 --> Jan 2025 | Trial primary completion date: Jul 2023 --> Jan 2025 Not yet recruiting --> Recruiting
- || ION582 / Ionis, Biogen
New P1/2 trial: HALOS: A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Multiple Ascending Doses of ION582 in Participants With Angelman Syndrome (clinicaltrials.gov) - Nov 18, 2021
P1/2, N=44, Not yet recruiting, Sponsor: Ionis Pharmaceuticals, Inc.